ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,07005
0,00%
Bitcoin
62.870,31
-1,36%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) News

BIIB

Biogen (BIIB)

Biogen Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BIIB
DatumZeitQuelleÜberschriftSymbolFirma
01/04/202401h30PR Newswire (US)Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDANASDAQ:BIIBBiogen Inc
06/03/202413h30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:BIIBBiogen Inc
04/03/202422h15GlobeNewswire Inc.Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingNASDAQ:BIIBBiogen Inc
27/02/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
23/02/202413h00GlobeNewswire Inc.Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPNASDAQ:BIIBBiogen Inc
22/02/202416h12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
22/02/202403h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202403h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202403h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202403h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202403h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202403h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202403h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
21/02/202416h24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
21/02/202403h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
14/02/202400h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
14/02/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
14/02/202400h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
14/02/202400h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
14/02/202400h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
14/02/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202423h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
13/02/202401h11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIIBBiogen Inc
13/02/202401h07Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIIBBiogen Inc
12/02/202422h06GlobeNewswire Inc.Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s AtaxiaNASDAQ:BIIBBiogen Inc
12/02/202417h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
10/02/202402h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
10/02/202402h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
10/02/202402h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
 Showing the most relevant articles for your search:NASDAQ:BIIB

Kürzlich von Ihnen besucht

TG
LHA
Deutsche Lufthansa
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
TG
NOV
Novo Nordisk
USOTC
RHHBY
Roche (QX)
PM
XAUUSD
Gold vs US Dollar
NASDAQ
MSFT
Microsoft
TG
RHM
Rheinmetall
TG
DBK
Deutsche Bank
TG
CBK
Commerzbank
TG
D7G
Nel ASA
NYSE
NKE
Nike
DBI
TDXP
Tec DAX
USOTC
BNPQY
BNP Paribas (QX)
TG
BAYN
Bayer
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten